Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings | Synapse
March 19, 2026Open Access
Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings
Key Points
To evaluate the real-world efficacy, safety, and quality of life associated with once-weekly somatrogon for children with growth hormone deficiency.
Case series analysis of children diagnosed with growth hormone deficiency
Comparison between once-weekly somatrogon and daily somatropin treatment
Assessment of quality of life and psychosocial outcomes
Somatrogon showed comparable efficacy to daily somatropin treatments
Safety profile of somatrogon was similar to that of conventional daily therapy
Quality of life and psychosocial outcomes remained stable during the treatment
Abstract
Once-weekly somatrogon demonstrated efficacy and safety comparable to daily somatropin with stable quality of life and psychosocial outcomes in children with GHD.